Site Editor

Gregory J. Riely, MD, PhD

Advertisement

Advertisement

News

Creating Better Utility of Test Results in EGFR-Mutated Metastatic NSCLC

News

New Application for Accelerated Approval for Dato-DXd in Advanced EGFR-Mutated NSCLC

Medical Literature

SABR for Early-Stage NSCLC: Dosimetric Variables That Matter Most

News

Chemoradiotherapy for Locally Advanced NSCLC: Is Dose Escalation the Answer to Local Tumor Control?

Medical Literature

Does Where Patients Live Affect Their Chances of Surviving Lung Cancer?

News

Insights on Concomitant Driver Alterations in EGFR-Mutated NSCLC

News

ESMO 2024: Targeting an Intestinal Bacterium to Improve Outcomes With Immunotherapy in NSCLC

Heather Wakelee, MD, on Clinical Implications of Latest Findings From IMpower010: Atezolizumab vs Best Supportive Care for NSCLC

Dominique Michaud, ScD, on DNA Methylation Patterns and Lung Cancer Detection

View More

Advertisement

JNCCN Spotlights

(NEW Update) Nivolumab in NSCLC

(NEW Update) Pembrolizumab in NSCLC

Dabrafenib + Trametinib (Tafinlar + Mekinist)

(UPDATE) Nivolumab (Opdivo) in NSCLC

Sotorasib

View More

More

News

ESMO 2024: Can Adding Corticosteroid to Radiotherapy for NSCLC Reduce Pneumonitis?

FDA Approves Tumor Treating Fields Therapy for Metastatic NSCLC

Amivantamab Plus Chemotherapy Approved by FDA for NSCLC With Certain Genetic Mutations

Atezolizumab Before and After Chemoradiation: Novel Plan for Unresectable Stage III NSCLC

ASCO Quality 2024: Can the Expansion of Medicaid Improve Clinical Outcomes in NSCLC?

Geriatric Assessment: Determining Optimal Treatment for Older Patients With NSCLC

ASTRO 2024: Role of Durvalumab With Radiotherapy for Some With Locally Advanced NSCLC

Novel Monoclonal Antibody Under Study in Phase III Trial of Nonsquamous NSCLC

View More

Advertisement

Published

Medical Literature

Selpercatinib vs Chemotherapy for RET Fusion–Positive NSCLC: Phase III Findings

CANOPY-1: Adding Monoclonal Antibody to Immunotherapy Regimen in NSCLC

Is There a Link Between Regional Influenza Activity and Mortality Among Patients With NSCLC?

CNS Activity in NSCLC: Osimertinib Plus Chemotherapy vs Osimertinib Monotherapy

View More

Ongoing

CE Activities

Improving Lung Cancer Care Through Understanding the Patient Experience

Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy

Implications of Recent Data Sets for the Current and Future Management of Lung Cancer

Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

View More

Available

Clinical Trials

LATIFY: Ceralasertib Plus Durvalumab vs Docetaxel in NSCLC Whose Disease Progressed on or After Prior Anti–PD(L)1 Therapy and Platinum-Based Chemotherapy

An Open-Label, Randomized, Multicenter, Phase III Study of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations

Study of Avutometinib (VS-6766) Plus Adagrasib in KRAS G12C NSCLC Patients

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in NSCLC

View More

Resources

For Your Patients

The American Lung Association

Bonnie J. Addario Lung Cancer Foundation

Caring Ambassadors Program

Dusty Joy Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2024 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.